Welcome to our dedicated page for Centessa Pharmaceuticals plc SEC filings (Ticker: CNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Centessa Pharmaceuticals plc filings document the regulatory record of a clinical-stage pharmaceutical issuer with American Depositary Shares listed on Nasdaq, each representing one ordinary share. Disclosures cover its orexin receptor 2 (OX2R) agonist focus, operating and financial results, corporate presentations, risk and capital-structure matters, and securities registered in connection with the ADS program.
Centessa's SEC filings also include Form 8-K material-event reports for underwriting and at-the-market sales agreements, public offerings of ADSs, executive and board changes, employment and advisory arrangements, and Regulation FD materials. Proxy filings describe governance, shareholder voting matters, compensation topics, and related public-company controls.
Centessa (NASDAQ:CNTA) Form 4 reports that Chief Business Officer Gregory M. Weinhoff exercised 10,000 options at $3.85 and immediately sold the same 10,000 ordinary shares on 06/25/2025 through a Rule 10b5-1 plan.
The shares were disposed at a weighted-average price of $13.8642, yielding roughly $139 k in gross proceeds and an implied ~$10 per-share spread. After the transactions he still owns 122,279 ordinary shares (≈8 % reduction versus post-exercise balance) and 65,000 unexercised options. The sale exceeds the 5 % materiality threshold for insider trades, making the activity noteworthy for investors tracking executive sentiment.
Centessa Pharmaceuticals (NASDAQ: CNTA) Form 4 shows General Counsel Iqbal J. Hussain exercised 12,000 stock options at $5.84 and immediately sold the same number of ordinary shares at a weighted-average $14.02 on 06/24/2025 under a Rule 10b5-1 plan.
Post-transaction, Hussain’s direct ownership declined by ~10% to 105,386 shares; he also holds 5,500 shares indirectly and 291,559 unexercised options.
- Gross sale proceeds ≈ $168.2 K.
- Sale represents >5% of insider’s pre-sale direct holdings, meeting materiality threshold.
- No impact on share count or dilution.
Insider selling by a senior legal officer can be viewed as a potential sentiment headwind, though execution under a pre-arranged 10b5-1 plan mitigates timing concerns.